Last updated on February 2018

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT ) regimen in peanut-allergic children.

Detailed Study Description

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT regimen for approximately 6 months in peanut-allergic children.

Clinical Study Identifier: NCT03126227

Contact Investigators or Research Sites near you

Start Over

Freddy Byrth

Sher Allergy Specialists - Center for Cough
Largo, FL United States
  Connect »